EPIWRITE
LIVE

Serial Number

98388195

Owner

Moonwalk Biosciences

Attorney

Michael J. Allan

Filing Date

Feb 2, 2024

Add to watchlist:

No watchlists yet
View on USPTO

EPIWRITE Trademark

Serial Number: 98388195

EPIWRITE is a trademark filed by Moonwalk Biosciences on February 2, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Moonwalk Biosciences (8 trademarks)

2 Tower Place, 17th Floor
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

February 2, 2024

Registration Date

Not Registered

Published for Opposition

January 7, 2025

Goods & Services

Pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases, age-related diseases in the nature of neurodegeneration, arthritis, cardiovascular disease, type 2 diabetes, cancer, and osteoporosis, and pediatric diseases in the nature of anemia, asthma, gastrointestinal disorders, skin conditions, neurological disorders, blood disorders, endocrine disorders, developmental or growth disorders, immunological disorders, obesity, and type 1 diabetes; Veterinary pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pulmonary, renal, reproductive, respiratory, and skeletal diseases, and age-related diseases in the nature of arthritis, thyroid imbalance, heart disease, kidney disease, cancer, endocrine disorders, liver disease, obesity, skin, respiratory, gastrointestinal and dental disease

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 24, 2026 NOAM
NEW NOA TO ISSUE
Jan 13, 2026 NEWN
NOTICE OF ALLOWANCE CANCELLED
Jan 13, 2026 IUCN
NOTICE OF REVIVAL - E-MAILED
Jan 6, 2026 NREV
PETITION TO REVIVE-GRANTED
Jan 6, 2026 PETG
TEAS PETITION TO REVIVE RECEIVED
Jan 6, 2026 PROA
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 6, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 5, 2026 ABN6
CORRECTED NOA E-MAILED
Jan 5, 2026 NOAC
DIVISIONAL PROCESSING COMPLETE
Jan 5, 2026 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 5, 2026 AITU
DIVISIONAL REQUEST RECEIVED
Jul 11, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Jul 11, 2025 ERTD
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 4, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 7, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 7, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 1, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 12, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 12, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 12, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 12, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 12, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 30, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 30, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 30, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 27, 2024 GNFN
FINAL REFUSAL E-MAILED
Aug 27, 2024 GNFR
FINAL REFUSAL WRITTEN
Aug 27, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 19, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 23, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 23, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 23, 2024 CNRT
ASSIGNED TO EXAMINER
May 22, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 29, 2024 NWOS
NEW APPLICATION ENTERED
Feb 6, 2024 NWAP